Zai Lab Partner argenx Report Results of Vyvgart (efgartigimod alfa-fcab) P-III (ADVANCE) Trial for Primary Immune Thrombocytopenia
Shots:
- The P-III (ADVANCE) trial evaluating Vyvgart in a ratio (2:1) in 131 patients with chronic & persistent ITP across the EU, North America & Japan for 24wks. The results from the (ADVANCE-SC) trial are expected in Q1’23
- The trial met its 1EPs i.e., patients achieved a sustained platelet response b/w 19 & 24wks. The 2EPs showed a significant benefit in the chronic ITP population & sustained platelet response in the overall population
- Additionally, 51.2% vs 20% were classified as IWG responders & 27.9% vs 4.4% as complete responders & showed platelet count improvement with significant separation from PBO @1wk. & maintained through 20wks., safety and tolerability were consistent with prior trials
Ref: Globenewswire | Image: Zai Lab
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
